Thank you so much. I want to welcome everybody to what I'm hoping will be a very lively and informative event. By way of introduction, this is a joint event, one of hopefully many that are joint educational offerings co-sponsored by not only SC&I, the Society of Cardiovascular Angiography and Interventions, but also the Society of Interventional Radiology. For those of you that remember, we did a joint educational series of events last year regarding peripheral intravascular ultrasound. And this year, with a kickoff of one of the first of many pivotal randomized trials looking at endovascular therapy for acute pulmonary embolism, we thought it was a great opportunity to do a joint event again. By way of background, my name is Robert Lookstein. I'm an interventional radiologist practicing in New York City. The people that have registered and logged in are largely interventional radiologists and interventional cardiologists. So I think we've tapped into the right market for this. We are hoping to have a very, very open and candid conversation about what the current state is of randomized trials and ongoing trials regarding the endovascular therapy for acute pulmonary embolism. I am humbled and honored to be joined by an incredible panel of esteemed faculty tonight that are accomplished clinical scientists and trialists in their own minds. I consider all of them professional colleagues and friends, and they're obviously devoting a significant amount of time to advancing the science in this space. I'm going to introduce them one by one, and then we'll pivot to a focused presentation of the recent release trial data from the peerless trial. First, my dear friend just down the block from me at Weill Cornell Medical Center, Aki Sista, who is professor of radiology. Aki is also internationally recognized as being the global principal investigator of the PE-TRAC trial, the only publicly funded trial looking at endovascular therapy for acute pulmonary embolism in the United States. Aki, thank you so much for joining us. Next is Eric Sesemsky, well known to I think everybody logging into this call. Eric is the director of vascular intervention at the B.I. Deaconess Medical Center and the section head for interventional cardiology and vascular research, and he's the director of the Smith Center for Outcomes Research at Harvard Medical School. Next is Jay Geary, who's the director of the cardiovascular cath lab and is associate professor of cardiovascular medicine at the Hospital of the University of Pennsylvania. Jay, thank you so much. Eric, thank you so much for joining us. Next is Julie Bowman, who is assistant professor of Harvard Medical School and the director of the B.I. Deaconess vascular lab. Julie, thank you. Next is June Lee, co-director of the vascular center and the pulmonary embolism response team at the Harrington Heart and Vascular Institute at University Hospitals of Cleveland. Again, it's great to see you, June. Thank you so much. And then again, lastly, as I mentioned, my name is Rob Lookstein. I'm an interventional radiologist in New York. Everybody on the panel is either in trial leadership or is principal investigator of either a free market IDE study or a randomized trial for pulmonary embolism or has been integrally involved with pulmonary embolism endovascular research trials so far. So we've tried to assemble a very diverse expert panel here that have extensive knowledge and expertise in the state of the science for endovascular therapy for pulmonary embolism. So again, thank you all for joining us this evening. We're going to talk about peerless, obviously, because that was recently presented on the podium at the recent TCT conference earlier this year. We're going to talk a little bit about how this trial affects our practice, and then we're going to pivot to really looking at what the future trials look like. There are several other pivotal randomized trials underway, several IDE studies, and I think it's really important to put peerless in the context of these other randomized trials and how they're going to affect the field moving forward for the next several years. And we've all made significant investments of our time to hopefully contributing to these randomized trials, and I think it's going to lead to a very, very lively discussion. These are the disclosures which are publicly available on the website where you logged in to register for this meeting. I'm not going to belabor it going over everyone's disclosures. We do want to thank our corporate partners, which are listed here. Thank you for your support. All of our corporate sponsors have made valuable investments in advancing the field and have all made significant contributions to furthering hopefully the science behind endovascular therapy for acute pulmonary embolism. I'm going to hand it over to my friend and colleague, Jay Geary, who's going to review the slides from the peerless study and hopefully lead us into a conversation about what peerless means for us as practicing clinicians and hopefully give us a forward sight into, again, how do we put this into the context of the remaining pivotal randomized trials that are currently underway. Jay, thank you so much for putting together this presentation tonight.

endovascular therapy

pulmonary embolism

peerless trial

interventional radiology

cardiovascular angiography